

Immune Design (IMDZ : US\$26.42)

Immune Design sinks 15% in 2015, underperforming 87% of the market

Immune Design Corporation, NASDAQ's 23rd largest Healthcare-Products company by market cap, sank US\$4.80 (or 15.4%) year to date in 2015 to close at US\$26.42. This means the stock has underperformed 87% of NASDAQ-listed stocks in 2015. Compared with the NASDAQ-100 Index which has risen 4.4% YTD, this is a relative price change of -19.8%. The volume YTD has been 1.3 times the average trading of 57,728 shares. In 2015 the market cap has declined US\$81 million.

Introduction with Trends

We are currently bearish on this stock in the long-term based on fundamental metrics, but are neutral in the short-term based on technical indicators

What makes us bearish on the stock is the following:

- The Q Ratio, defined by James Tobin as MCap divided by Total Assets, is 5.7. Compared with the rest of the market the stock is overvalued and ranks in the bottom 7% of stocks by value of Q Ratio.

However, there are some reasons why we remain neutral on the stock for the short-term:

- Its Moving Average Convergence Divergence indicators are rising, with its 12-day EMA higher than its 26-day EMA.
- The price to 200-day MAP ratio is 0.76, a bearish indicator.
- It has outperformed 67% of the market the past 6 months.
- In the last three months the number of falls outnumbered rises 33:29 or 1.14:1.

Stock Summary

Sector	Healthcare-Products
Market Cap	US\$445.9 million
Shares Outstanding	16,878,817
ISIN	US45252L1035
Relative Strength (3 mo)	13

MCap: A Historical Perspective

	Share Price (USD)	Market Cap (US\$)
Last	26.4	445.9 million

Analysis

Bearish Signals

- Falls to Rises: In the last three months the number of falls outnumbered rises 33:29 or 1.14:1.
- The Price/MAP of 0.76 for IMDZ is lower than the Price/MAP for the NASDAQ-100 Index of 0.9.
- The price to 200-day MAP ratio is 0.76, a bearish indicator. In the past 200 days this ratio has been under 0.76 just seven times suggesting a support level. The stock is trading below both its MAPs and the 50-day MAP of US\$33.63 is lower than the 200-day MAP of US\$34.90, another bearish indicator.

Overvaluation:

- Price/Sales of 69.32 versus sector average of 1.8 and market average of 2.4.
- The Q Ratio, defined by James Tobin as MCap divided by Total Assets, is 5.7. Compared with the rest of the market the stock is overvalued and ranks in the bottom 7% of stocks by value of Q Ratio.

Other Bearish Signals:

The stock has a score of merely 1 out of 9 set by Joseph Piotroski [pass mark ≥ 5]:

Improvement in asset turnover [growth in revenue of 302.3% exceeded growth in assets of 153.1%].

Bearish Indicators and Rank in Market:

Description	Value	Rank In Market
Price Change %	-0.3	In Bottom Quartile
Price to Book Value	6.7	In Bottom Quartile
Price/MAP50	0.79	In Bottom Quartile
Price/MAP200	0.76	In Bottom Quartile
Annual Revenue	US\$6.4 million	In Bottom 4%
%Prem To Vol Wtd Price	0.1	In Bottom 3%

Note

- The price is equal to its 1-month volume weighted average price of US\$26.38.

Neutral Indicators and Rank in Market:

Description	Value	Rank In Market
MCap	US\$445.9 million	In 2nd Quartile
Turnover in Quarter	US\$150.1 million	In 3rd Quartile

Bullish Signals:


- In the NASDAQ market of 2,406 stocks and 1 unit traded today, the stock has a 6-month relative strength of 67 which means it has outperformed 67% of the market.
- The Moving Average Convergence Divergence (MACD) indicator of 12-day Exponential Moving Average (EMA) of 26.06 minus the 26-day EMA of 25.83 is positive suggesting a bullish signal. Both the 12-day EMA as well as the 26-day EMA are rising, another bullish signal.
- The current short volume is 0.4 times its own historical average of 0.1%. It plummeted 87.3% from the previous day, plummeted 73.2% from a week ago and plummeted 74.2% from a month ago, a significant bullish indicator.

Undervaluation:

- The company is cash rich with Cash to Market Capitalisation at 16.9%.

Other Bullish Signals:

% Growth Y.O.Y, Revenue & Net Profit



Also, the following criteria set by Benjamin Graham:


- "Current ratio of two or more"; current assets are 6.5 times current liabilities.

Analysis (continued)


Insider Trades




YTD Comparison Stock Sector Index



Relative Strength




Turnover Rate & Turnover Period




Trailing 3 months

Turnover	US\$150.1 million
Volume	5,751,968
Volume Index (1 is avg)	1.6

Weekly Price Volume Dynamics (Last 12 Weeks)



Stock v Index (Trailing Year)



Price/Moving Average Price [P/MAP]



Peer Group Analysis

Name	Last Price	Relative strength (6-months)	MCap (USD)	PV \$1000 (1 yr)	Revenue (USD)	Net Profit (USD)	Total Assets (USD)
NutriSystem	US\$19.68	76	566.2M	1,413	403.1M	19.3M	109.9M
Ocular Therapeutix	US\$26.50	97	565M	0	772,000	(28.7M)	78.2M
Synutra International	US\$7.80	87	446.9M	1,361	375.9M	30.9M	550.7M
Immune Design	US\$26.42	67	445.9M	0	6.4M	(34.2M)	78.4M
T2 Biosystems	US\$17.57	72	352.1M	0	119,000	(36M)	79.1M
Angie'S List	US\$5.88	8	344.4M	477	315M	(12.1M)	154.5M
Chemocentryx	US\$7.89	88	342M	1,489		(46.9M)	117M

Recent Analyst Recommendations

Date	Brokerage	Action	Past Rating	Current Rating	Prev Target	Price Target
01-Apr-2015	Jefferies Group	Upgrade	Hold	Buy	32	29

Company Overview

Activities

Immune Design Corporation develops therapeutic vaccines. The Company creates synthetic compounds to boost the effectiveness of vaccines, and technology designed to trigger a specific immune defense against viral and bacterial pathogens. Immune Design provides its product to treat infectious diseases, cancer, and allergies.

Further details can be found at
www.immunedesign.com/.

Economic Sector

Healthcare

Regulatory Announcements

Key Developments

April 16: Immune Design Prices Public Offering of Common Stock

[News Story] SEATTLE and SOUTH SAN FRANCISCO, Calif., April 15, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ) today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a price to the public of \$26.50 per share for total gross proceeds of approximately \$79.5 million, before deducting underwriting discounts and commissions and estimated expenses.

[For more details click here.](#)

Financial Results

March 31: Immune Design Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update

[News Story] SEATTLE and SOUTH SAN FRANCISCO, Calif., March 31, 2015 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ), a clinical-stage immunotherapy company, today reported financial results and provided a corporate update for the fourth quarter and full year ending December 31, 2014.

"2014 was a transformational year for Immune Design: initiating the clinical development of the company's two in vivo immuno-oncology approaches to fighting cancer; the progress of our partner's programs outside of oncology; and the validation of both new partnerships and the public investors behind our successful IPO," said Carlos V.

[For more details click here.](#)

March 31: Immune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-Oncology Agents

[News Story] SEATTLE and SAN FRANCISCO, March 31, 2015 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, reported today that analyses of data from three ongoing Phase 1 studies support continued development of its two primary product candidates, CMB305 and G100.

CMB305 and G100 represent Immune Design's two distinct approaches to fighting cancer via the in vivo induction and/or expansion of anti-tumor CD8 T cells.

[For more details click here.](#)

March 26: Immune Design Announces Treatment of Patients With CMB305 Investigational Immuno-Oncology Agent

[News Story]

Prime-Boost in vivo T cell active immunotherapy

SEATTLE and SOUTH SAN FRANCISCO, Calif., March 26, 2015 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the dosing of patients in a Phase 1b clinical trial of CMB305, a "prime-boost" immuno-oncology product candidate generated from the company's ZVex™ and GLAAS™ platforms.

[For more details click here.](#)

Conferences/Exhibitions

March 23: Events Calendar: Immune Design Announces Upcoming Financial Results and Immuno-oncology Conference Presentation

[News Story]

Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report fourth quarter and year-end 2014 financial results at the closing of U.S. financial markets on Tuesday, March 31, 2015. Immune Design management will host a webcast and conference call at 1:30 p.m.

[For more details click here.](#)

Board and Management

March 19: Immune Design appoints Director

Immune Design has appointed Lewis W. Coleman as a Director. The effective date is March 19, 2015.

[For more details click here.](#)

Company Overview (continued)

March 11: Immune Design: Delaware Court of Chancery Decision Denies Theravectys Motion for Preliminary Injunction

[News Story] SEATTLE & SOUTH SAN FRANCISCO--(BUSINESS WIRE)-- Immune Design Corp. (Nasdaq:IMDZ), a clinical-stage immunotherapy company, today announced that the Delaware Court of Chancery yesterday denied Theravectys SA's ("TVS") request for a preliminary injunction that sought to enjoin Immune Design from continuing critical development activities relating to its lentiviral vector technology.

"The Immune Design team appreciates the court's careful consideration of the evidence and the legal issues before it, and we are pleased with the Court's decision to deny Theravectys' motion, which we expect would have interfered with our important goal of improving the lives of cancer patients," said Carlos Paya, MD, PhD, President and CEO of Immune Design.

[For more details click here.](#)

8-K people news

April 20: Lewis W. Coleman - Immune Design updates director's profile 20 April 2015

Immune Design recently released their definitive SEC filing DEF 14A. The updated profile of Lewis W. Coleman (73), Director is shown below. Lewis Coleman has served as a member of our Board since March 2015. Mr. Coleman was appointed as President of DreamWorks Animation SKG, Inc. in December 2005 and served as Chief Financial Officer beginning March 2007 until his appointment as Vice Chairman in July 2014. In addition, Mr. Coleman was a member of the board of directors of DreamWorks Animation from October 2004 until December 2005, and again from December 2006 until January 2015. Mr. Coleman served on the board of directors of Northrop Grumman Corporation from 2001 until November 2012 and as lead independent director and non-executive Chairman from January 2010 until July 2011. He was the President of the Gordon and Betty Moore Foundation from its founding in November 2000 to December 2004. Prior to that, Mr. Coleman was employed by Banc of America Securities, formerly known as Montgomery Securities, where he was a Senior Managing Director from 1995 to 1998 and Chairman from 1998 to 2000. Before he joined Montgomery Securities, Mr. Coleman spent ten years at the Bank of America and Bank of America Corporation where he held roles as the Head of Capital Markets, Head of the World Banking Group, and Vice Chairman of the board and Chief Financial Officer. He spent the previous thirteen years at Wells Fargo Bank where his positions included Head of International Banking, Chief Personnel Officer and Chairman of the Credit Policy Committee. He received a B.A. in economics from Stanford University. He is a fellow of the National Academy of Arts and Sciences and a member of the board of directors of Global Crop Diversity Trust, a UN Chartered Non-Profit organization. He also serves on the board of directors of DCI, LLC, a private fund management company, and is Chairman of the board of eBond Advisors, a private financial technology company. Mr. Coleman's extensive banking and financial experience and board and executive leadership skills with multiple public and private companies gives him the qualifications, skills and financial expertise to serve on our Board.

Company Overview (continued)

April 20: Ed Penhoet - Immune Design updates chairman and director's profile 20 April 2015

Immune Design recently released their definitive SEC filing DEF 14A. The updated profile of Ed Penhoet (74), Chairman and Director is shown below. Ed Penhoet, Ph.D. has served as a member of our Board since June 2008 and chairman of the board since January 2013. Since June 2000, Dr. Penhoet has been a Director of Alta Partners. He sits on the board of several public and private life sciences companies, including CymaBay Therapeutics, Inc., Scynexis, Inc. and aTYR Pharma, Inc. Dr. Penhoet was the founder of Chiron Corporation, a biotechnology company, where he served as President and Chief Executive Officer from June 1981 to April 1998. Dr. Penhoet recently served as the President of the Gordon and Betty Moore Foundation from June 2004 to January 2008. Earlier, from September 1971 to July 1981, Dr. Penhoet was a faculty member of the Biochemistry Department and Dean of the School of Public Health at the University of California, Berkeley. He was the Dean of the School of Public Health at the University of California, Berkeley from July 1998 to June 2002. Dr. Penhoet has an A.B. in biology from Stanford University and a Ph.D. from the University of Washington. We believe that Dr. Penhoet's experience in the venture capital industry, serving as a director of other publicly traded and privately held life science companies and founding and serving as President and Chief Executive Officer of a public life science company, gives him the qualifications, skills and financial expertise to serve on our Board.

April 20: Brian Atwood - Immune Design updates director's profile 20 April 2015

Immune Design recently released their definitive SEC filing DEF 14A. The updated profile of Brian Atwood (62), Director is shown below. Brian Atwood has served as a member of our Board since May 2008. Mr. Atwood co-founded Versant Ventures in December 1999 where he serves as a managing director, after spending four years at Brentwood Venture Capital where he served as a general partner. Prior to launching his career in venture capital, he was the founder of Glycomed Inc., a publicly traded biotechnology company, where he served as President and Chief Executive Officer from December 1993 to 1995. Prior to Glycomed, Mr. Atwood was a general partner of Brentwood Venture Capital from November 1995 to October 1998. From January 1986 to June 1987, Mr. Atwood co-founded and served as director of Perkin Elmer/Cetus Instruments, a joint venture for robotics automation and genomics research instruments and products later acquired by Perkin Elmer. Mr. Atwood currently serves as a board member at the several public and private companies, including Five Prime Therapeutics, Inc., Veracyte, Inc. and Clovis Oncology, Inc., each of which is a public biopharmaceutical company. Mr. Atwood received a Bachelor's degree in Biological Sciences from the University of California, Irvine, a Master's degree from the University of California, Davis, and an MBA from Harvard Business School. We believe that Mr. Atwood's experience in the venture capital industry, serving as a director of other publicly traded and privately held life science companies and founding and serving as President and Chief Executive Officer of a life science company, gives him the qualifications, skills and financial expertise to serve on our Board.

April 20: Peter Svernilson - Immune Design updates director's profile 20 April 2015

Immune Design recently released their definitive SEC filing DEF 14A. The updated profile of Peter Svernilson (53), Director is shown below. Peter Svernilson has served as a member of our Board since March 2013. In February 2007, Mr. Svernilson founded The Column Group, LP, a venture capital firm, and currently serves as its managing partner. Since January 2008, he has served as chairman of the board of Seragon Pharmaceuticals. Mr. Svernilson has also served as a member of the board of NGM Biopharmaceuticals since January 2008. He was the chairman of the board of Aragon Pharmaceuticals from May 2009 until it was acquired by Johnson & Johnson in August 2013. Mr. Svernilson was a board member of PTC Therapeutics from September 2010 until March 2013. Prior to founding The Column Group, LP, he founded Three Crowns Capital, where he served as its managing partner from June 1996 to February 2007. From 1996 to 2006, Mr. Svernilson served as a board member of numerous biotech companies, including Rosetta Informatics, PTC Therapeutics, ChemoCentryx and Somalogic. Prior to Three Crowns Capital, he was the associate managing director in charge of European Investment Banking Origination at Nomura Securities in London. Mr. Svernilson is currently a Trustee for The Institute for Advanced Study in Princeton, New Jersey. Mr. Svernilson received an M.B.A. from the Stockholm School of Economics and Finance. We believe that Mr. Svernilson's experience in the venture capital industry and serving as a director of other publicly traded life science companies gives him the qualifications, skills and financial expertise to serve on our Board.

April 20: Carlos Paya - Immune Design updates CEO, director and president's profile 20 April 2015

Immune Design recently released their definitive SEC filing DEF 14A. The updated profile of Carlos Paya (56), CEO, Director and President is shown below. Carlos Paya, M.D., Ph.D. We entered into an employment agreement with Dr. Paya in June 2014, for the position of President and Chief Executive Officer. Pursuant to Dr. Paya's employment agreement, he was entitled to an initial annual base salary of \$515,000, which may be increased (or decreased) from time to time based on the review of our Compensation Committee. Dr. Paya's annual base salary was increased to \$530,450 in January 2015. Dr. Paya is eligible for annual performance bonuses based upon criteria established by our board. Dr. Paya's annual target bonus is 50% of his annual base salary. Dr. Paya is eligible to participate in our employee benefit plans on the same terms as other regular, full-time employees.

Company Overview (continued)

April 20: Franklin Berger - Immune Design updates director's profile 20 April 2015

Immune Design recently released their definitive SEC filing DEF 14A. The updated profile of Franklin Berger (65), Director is shown below. Franklin Berger has served as a member of our Board since March 2014. Mr. Berger worked at Sectoral Asset Management as a founder of the small-cap focused NEMO Fund from January 2007 through June 2008. From May 1998 to March 2003, he served at J.P. Morgan Securities, most recently as Managing Director, Equity Research and Senior Biotechnology Analyst. Previously, Mr. Berger served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger also serves on the boards of directors of BELLUS Health, Inc., ESSA Pharma, Inc. and Five Prime Therapeutics, Inc., each of which is a public biotechnology company. Mr. Berger previously served as a member of the boards of directors of Seattle Genetics, Inc., Aurinia Pharmaceuticals, Inc., Emisphere Technologies, Inc., BioTime, Inc. and VaxGen, Inc., each of which were public biotechnology or biopharmaceutical companies during Mr. Berger's service as a director. Mr. Berger received a B.A. in International Relations and an M.A. in International Economics both from Johns Hopkins University and an M.B.A. from the Harvard Business School. Mr. Berger's financial background and experience as an equity analyst in the biotechnology industry combined with his experience serving on the boards of directors of multiple public companies is important to our strategic planning and financing activities and give him the qualifications, skills and financial expertise to serve on our Board.

April 20: William Ringo - Immune Design updates director's profile 20 April 2015

Immune Design recently released their definitive SEC filing DEF 14A. The updated profile of William Ringo (69), Director is shown below. William Ringo has served as a member of our Board since February 2014. Mr. Ringo is a senior advisor to Barclays Healthcare Group and a strategic advisor to Sofinnova Ventures, where he has served since June 2010 and June 2010, respectively. From April 2008 until his retirement in April 2010, Mr. Ringo was Senior Vice President of Business Development, Strategy and Innovation at Pfizer Inc., a publicly traded pharmaceutical company, and was responsible for guiding Pfizer's overall strategic planning and business development activities. Prior to joining Pfizer, he served as an executive in residence at Warburg Pincus and Sofinnova Ventures. From August 2004 to April 2006, Mr. Ringo was President and Chief Executive Officer of Abgenix, Inc., a biotechnology firm focused on developing human antibodies as agents to treat cancer and other serious diseases. Mr. Ringo began his career at Eli Lilly & Company in 1973 and during his 28-year tenure he held a number of senior positions, including Product Group President for Oncology and Critical Care, President of Internal Medicine Products, President of the Infectious Diseases Business Unit and Vice President of Sales and Marketing for U.S. Pharmaceuticals. He retired from Lilly in February 2001. Mr. Ringo also serves on the boards of directors of Five Prime Therapeutics, Inc., Dermira, Inc., Mirati Therapeutics, Inc., Sangamo BioSciences, Inc. and Assembly Biosciences, Inc., each of which is a public biotechnology or biopharmaceutical company. From March 2001 to December 2007, he served on various boards of directors, including Encysive Pharmaceuticals, Inc., Inspire Pharmaceuticals, Inc. and InterMune, Inc. where he was the non-executive chairman of the board after serving as interim Chief Executive Officer from June 2003 to September 2003. He also serves on the board of directors of BioCrossroads, a public-private collaboration of corporate, university, government and entrepreneurial leaders that supports Indiana's life sciences research and corporate strengths in life sciences while encouraging business development in the region. He received a B.S. in business administration and an M.B.A. from the University of Dayton. We believe that Mr. Ringo's experience in the venture capital industry, serving as an executive and director of other publicly traded and privately held life science companies, gives him the qualifications, skills and financial expertise to serve on our Board.

8-K other news

March 31: Immune Design: Results of Operations and Financial Condition

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1437786_000162828015002075_0001628280-15-002075.txt

Source: 8-K United States Securities and Exchange Commission

Company Overview (continued)

March 11: Immune Design: Other Events

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1437786_000119312515086409_0001193125-15-086409.txt

Source: 8-K United States Securities and Exchange Commission

March 10: Immune Design: Other Events

[News Story]


http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1437786_000119312515084340_0001193125-15-084340.txt

Source: 8-K United States Securities and Exchange Commission

Issued Capital

Based on 16,878,817 issued equity shares the market capitalisation is US\$445.9 million. It is NASDAQ's 28th largest Healthcare-Products company by assets. The top sixteen shareholders hold 31.8% of the issued capital leaving a float of 68.2%.

Top 16 Institutional Holdings



Top 10 Shareholders

Name of Shareholder	No. of Shares	% Held
Column Group L P	3,161,942	18.73
Fmr Llc	818,764	4.85
Franklin Resources Inc	738,026	4.37
Jpmorgan Chase & Co	229,450	1.36
Cormorant Asset Management Llc	140,000	0.83
Vanguard Group Inc	60,180	0.36
Barclays Global Investors Uk Holdings Ltd	47,766	0.28
Numeric Investors Llc	37,012	0.22
Goldman Sachs Group Inc	36,652	0.22
Sectoral Asset Management Inc	21,181	0.13
Total	5,290,973	31.35

Board and Management

Carlos Paya
CEO & President & Director



Carlos Paya, M.D., Ph.D. We entered into an employment agreement with Dr. Paya in June 2014, for the position of President and Chief Executive Officer. Pursuant to Dr. Paya's employment agreement, he was entitled to an initial annual base salary of \$515,000, which may be increased (or decreased) from time to time based on the review of our Compensation Committee. Dr. Paya's annual base salary was increased to \$530,450 in January 2015. Dr. Paya is eligible for annual performance bonuses based upon criteria established by our board. Dr. Paya's annual target bonus is 50% of his annual base salary. Dr. Paya is eligible to participate in our employee benefit plans on the same terms as other regular, full-time employees.

Ed Penhoet
Chairman & Director

Ed Penhoet, Ph.D. has served as a member of our Board since June 2008 and chairman of the board since January 2013. Since June 2000, Dr. Penhoet has been a Director of Alta Partners. He sits on the board of several public and private life sciences companies, including CymaBay Therapeutics, Inc., Scynexis, Inc. and aTYR Pharma, Inc. Dr. Penhoet was the founder of Chiron Corporation, a biotechnology company, where he served as President and Chief Executive Officer from June 1981 to April 1998. Dr. Penhoet recently served as the President of the Gordon and Betty Moore Foundation from June 2004 to January 2008. Earlier, from September 1971 to July 1981, Dr. Penhoet was a faculty member of the Biochemistry Department and Dean of the School of Public Health at the University of California, Berkeley. He was the Dean of the School of Public Health at the University of California, Berkeley from July 1998 to June 2002. Dr. Penhoet has an A.B in biology from Stanford University and a Ph.D. from the University of Washington. We believe that Dr. Penhoet's experience in the venture capital industry, serving as a director of other publicly traded and privately held life science companies and founding and serving as President and Chief Executive Officer of a public life science company, gives him the qualifications, skills and financial expertise to serve on our Board.

Peter Svernilson
Director

Peter Svernilson has served as a member of our Board since March 2013. In February 2007, Mr. Svernilson founded The Column Group, LP, a venture capital firm, and currently serves as its managing partner. Since January 2008, he has served as chairman of the board of Seragon Pharmaceuticals. Mr. Svernilson has also served as a member of the board of NGM Biopharmaceuticals since January 2008. He was the chairman of the board of Aragon Pharmaceuticals from May 2009 until it was acquired by Johnson & Johnson in August 2013. Mr. Svernilson was a board member of PTC Therapeutics from September 2010 until March 2013. Prior to founding The Column Group, LP, he founded Three Crowns Capital, where he served as its managing partner from June 1996 to February 2007. From 1996 to 2006, Mr. Svernilson served as a board member of numerous biotech companies, including Rosetta Informatics, PTC Therapeutics, ChemoCentryx and Somalogic. Prior to Three Crowns Capital, he was the associate managing director in charge of European Investment Banking Origination at Nomura Securities in London. Mr. Svernilson is currently a Trustee for The Institute for Advanced Study in Princeton, New Jersey. Mr. Svernilson received an M.B.A. from the Stockholm School of Economics and Finance. We believe that Mr. Svernilson's experience in the venture capital industry and serving as a director of other publicly traded life science companies gives him the qualifications, skills and financial expertise to serve on our Board.

Board and Management (continued)

Brian Atwood Director

Brian Atwood has served as a member of our Board since May 2008. Mr. Atwood co-founded Versant Ventures in December 1999 where he serves as a managing director, after spending four years at Brentwood Venture Capital where he served as a general partner. Prior to launching his career in venture capital, he was the founder of Glycomed Inc., a publicly traded biotechnology company, where he served as President and Chief Executive Officer from December 1993 to 1995. Prior to Glycomed, Mr. Atwood was a general partner of Brentwood Venture Capital from November 1995 to October 1998. From January 1986 to June 1987, Mr. Atwood co-founded and served as director of Perkin Elmer/Cetus Instruments, a joint venture for robotics automation and genomics research instruments and products later acquired by Perkin Elmer. Mr. Atwood currently serves as a board member at the several public and private companies, including Five Prime Therapeutics, Inc., Veracyte, Inc. and Clovis Oncology, Inc., each of which is a public biopharmaceutical company. Mr. Atwood received a Bachelor's degree in Biological Sciences from the University of California, Irvine, a Master's degree from the University of California, Davis, and an MBA from Harvard Business School. We believe that Mr. Atwood's experience in the venture capital industry, serving as a director of other publicly traded and privately held life science companies and founding and serving as President and Chief Executive Officer of a life science company, gives him the qualifications, skills and financial expertise to serve on our Board.

William Ringo Director

William Ringo has served as a member of our Board since February 2014. Mr. Ringo is a senior advisor to Barclays Healthcare Group and a strategic advisor to Sofinnova Ventures, where he has served since June 2010 and June 2010, respectively. From April 2008 until his retirement in April 2010, Mr. Ringo was Senior Vice President of Business Development, Strategy and Innovation at Pfizer Inc., a publicly traded pharmaceutical company, and was responsible for guiding Pfizer's overall strategic planning and business development activities. Prior to joining Pfizer, he served as an executive in residence at Warburg Pincus and Sofinnova Ventures. From August 2004 to April 2006, Mr. Ringo was President and Chief Executive Officer of Abgenix, Inc., a biotechnology firm focused on developing human antibodies as agents to treat cancer and other serious diseases. Mr. Ringo began his career at Eli Lilly & Company in 1973 and during his 28-year tenure he held a number of senior positions, including Product Group President for Oncology and Critical Care, President of Internal Medicine Products, President of the Infectious Diseases Business Unit and Vice President of Sales and Marketing for U.S. Pharmaceuticals. He retired from Lilly in February 2001. Mr. Ringo also serves on the boards of directors of Five Prime Therapeutics, Inc., Dermira, Inc., Mirati Therapeutics, Inc., Sangamo BioSciences, Inc. and Assembly Biosciences, Inc., each of which is a public biotechnology or biopharmaceutical company. From March 2001 to December 2007, he served on various boards of directors, including Encysive Pharmaceuticals, Inc., Inspire Pharmaceuticals, Inc. and InterMune, Inc. where he was the non-executive chairman of the board after serving as interim Chief Executive Officer from June 2003 to September 2003. He also serves on the board of directors of BioCrossroads, a public-private collaboration of corporate, university, government and entrepreneurial leaders that supports Indiana's life sciences research and corporate strengths in life sciences while encouraging business development in the region. He received a B.S. in business administration and an M.B.A. from the University of Dayton. We believe that Mr. Ringo's experience in the venture capital industry, serving as an executive and director of other publicly traded and privately held life science companies, gives him the qualifications, skills and financial expertise to serve on our Board.

Board and Management (continued)

Franklin Berger Director

Franklin Berger has served as a member of our Board since March 2014. Mr. Berger worked at Sectoral Asset Management as a founder of the small-cap focused NEMO Fund from January 2007 through June 2008. From May 1998 to March 2003, he served at J.P. Morgan Securities, most recently as Managing Director, Equity Research and Senior Biotechnology Analyst. Previously, Mr. Berger served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger also serves on the boards of directors of BELLUS Health, Inc., ESSA Pharma, Inc. and Five Prime Therapeutics, Inc., each of which is a public biotechnology company. Mr. Berger previously served as a member of the boards of directors of Seattle Genetics, Inc., Aurinia Pharmaceuticals, Inc., Emisphere Technologies, Inc., BioTime, Inc. and VaxGen, Inc., each of which were public biotechnology or biopharmaceutical companies during Mr. Berger's service as a director. Mr. Berger received a B.A. in International Relations and an M.A. in International Economics both from Johns Hopkins University and an M.B.A. from the Harvard Business School. Mr. Berger's financial background and experience as an equity analyst in the biotechnology industry combined with his experience serving on the boards of directors of multiple public companies is important to our strategic planning and financing activities and give him the qualifications, skills and financial expertise to serve on our Board.

Lewis W. Coleman Director

Lewis Coleman has served as a member of our Board since March 2015. Mr. Coleman was appointed as President of DreamWorks Animation SKG, Inc. in December 2005 and served as Chief Financial Officer beginning March 2007 until his appointment as Vice Chairman in July 2014. In addition, Mr. Coleman was a member of the board of directors of DreamWorks Animation from October 2004 until December 2005, and again from December 2006 until January 2015. Mr. Coleman served on the board of directors of Northrop Grumman Corporation from 2001 until November 2012 and as lead independent director and non-executive Chairman from January 2010 until July 2011. He was the President of the Gordon and Betty Moore Foundation from its founding in November 2000 to December 2004. Prior to that, Mr. Coleman was employed by Banc of America Securities, formerly known as Montgomery Securities, where he was a Senior Managing Director from 1995 to 1998 and Chairman from 1998 to 2000. Before he joined Montgomery Securities, Mr. Coleman spent ten years at the Bank of America and Bank of America Corporation where he held roles as the Head of Capital Markets, Head of the World Banking Group, and Vice Chairman of the board and Chief Financial Officer. He spent the previous thirteen years at Wells Fargo Bank where his positions included Head of International Banking, Chief Personnel Officer and Chairman of the Credit Policy Committee. He received a B.A. in economics from Stanford University. He is a fellow of the National Academy of Arts and Sciences and a member of the board of directors of Global Crop Diversity Trust, a UN Chartered Non-Profit organization. He also serves on the board of directors of DCI, LLC, a private fund management company, and is Chairman of the board of eBond Advisors, a private financial technology company. Mr. Coleman's extensive banking and financial experience and board and executive leadership skills with multiple public and private companies gives him the qualifications, skills and financial expertise to serve on our Board.

Creation of shareholder value in Immune Design:

Since appointment as Director: The present value of USD1,000 invested on the appointment date of March 19, 2015 at close price of US\$27.79 is US\$951, for a capital loss of US\$49.

Financial Results (Annual)

31 December, 2014

Annual Report for the year ended December 31, 2014

year-on-year comparisons with previous corresponding period

Favourable Changes

- EPS continued to be negative like in the previous year
- However, there was an improvement from \$US-43.48 in the previous year to \$US-4.56
- Total liabilities to total assets down 11.8% to 0.2.


Unfavourable Changes

- Current ratio down 58.0% to 6.5
- Operating cash flow is negative
- Working capital to total assets down 9.1% to 84.2%.

Major Common Size Ratios

- Total current assets to total assets up from 99.0% to 99.5%
- Cash to total assets down from 98.1% to 96.1%
- Current debtors to total assets up from 0.3% to 2.5%
- Fixed assets to total assets down from 1.0% to 0.5%
- Cost of goods sold to sales down from 41.8% to 9.9%.

Year on Year Revenue & Net Profit (In USD millions)



INCOME STATEMENT

Currency in Thousand of USD	2014-12-31	2013-12-31	Change %
Revenues:			
Licensing revenue	4,500	729	Up 517.3
Product sales	881	870	Up 1.3
Other, net	1,052		
Total revenues	6,433	1,599	Up 302.3

Financial Results (Annual) (continued)

31 December, 2014

Operating expenses:			
Cost of product sales	638	669	Down 4.6
Research and development	22,746	11,554	Up 96.9
General and administrative	12,927	4,433	Up 191.6
Total operating expenses	36,311	16,656	Up 118.0
Loss from operations	-29,878	-15,057	Deterioration 98.4
Interest and other income	4	37	Down 89.2
Change in fair value of convertible preferred stock warrant liability	-4,277	-955	Deterioration 347.9
Net loss attributable to common stockholders	-34,151	-15,975	Deterioration 113.8
Basic and diluted net loss per share attributable to common stockholders	-456.0c	-4,348.0c	Reduced 89.5
Weighted-average shares used to compute basic and diluted net loss per share attributable to common stockholders	7,494,790	367,437	Up 1,939.7

BALANCE SHEET

Currency in Thousand of USD	2014-12-31	2013-12-31	Change %
Assets			
Current assets:			
Cash and cash equivalents	75,354	30,387	Up 148.0
Accounts receivable	1,970	87	Up 2,164.4
Inventory	25	17	Up 47.1
Prepaid expenses	633	179	Up 253.6
Total current assets	77,982	30,670	Up 154.3
Property and equipment, net	401	295	Up 35.9
Total assets	78,383	30,965	Up 153.1
Liabilities, convertible preferred stock, and stockholders' equity			
Current liabilities:			
Accounts payable	6,903	866	Up 697.1
Accrued liabilities	5,001	1,082	Up 362.2
Deferred rent, current	43	27	Up 59.3
Total current liabilities	11,947	1,975	Up 504.9
Other noncurrent liabilities	90	94	Down 4.3
Convertible preferred stock warrant liability		3,336	
	12,037	5,405	Up 122.7
Commitments and contingencies			
Convertible preferred stock, 0.001 par value per share; 10,000,000 and 12,882,593 shares authorized at December31, 2014 and 2013, respectively; zero and 9,769,422 shares issued and outstanding at December31, 2014 and 2013, respectively; liquidation preference of zero and 84,300 at December31, 2014 and 2013, respectively		81,394	

Financial Results (Annual) (continued)

31 December, 2014

Stockholders' equity (deficit):

Common stock, 0.001 par value per share; 100,000,000 and 17 15,045,871 shares authorized at December31, 2014 and 2013, respectively; 16,878,817 and 369,460 shares issued and outstanding at December31, 2014 and 2013, respectively		3	Up 466.7
Additional paid-in capital	157,092	775	Up 20,169.9
Accumulated deficit	-90,763	-56,612	Deterioration 60.3
Total stockholders' equity (deficit)	66,346	-55,834	Recovery
Total liabilities, convertible preferred stock and stockholders' equity	78,383	30,965	Up 153.1

CASH FLOW

Currency in Thousand of USD	2014-12-31	2013-12-31	Change %
Operating activities			
Net loss	-34,151	-15,975	Deterioration 113.8
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation and amortization	238	407	Down 41.5
Stock-based compensation expense	1,344	255	Up 427.1
Revaluation of convertible preferred stock warrant liability	4,277	955	Up 347.9
Other		94	
Changes in operating assets and liabilities:			
Accounts receivable	-1,883	426	Deterioration
Inventory	-8	109	Deterioration
Prepaid expenses	-454	8	Deterioration
Accounts payable	6,037	-213	Recovery
Accrued liabilities	3,955	-453	Recovery
Deferred rent	-24	89	Deterioration
Net cash used in operating activities	-20,669	-14,298	Deterioration 44.6
Investing activities			
Purchases of property and equipment	-344	-175	Deterioration 96.6
Proceeds from the sale of property and equipment		43	
Net cash used in investing activities	-344	-132	Deterioration 160.6

Financial Results (Annual) (continued)

31 December, 2014

Financing activities

Net proceeds from issuance of common stock upon initial public offering 57,807

Proceeds from exercise of preferred stock warrants 8,150

Proceeds from exercise of stock options 23 6 Up 283.3

Proceeds from sale of convertible preferred stock, net of cash paid for issuance costs 29,668

Proceeds from sale of convertible preferred stock warrants 2,381

Net cash provided by financing activities 65,980 32,055 Up 105.8

Net increase in cash and cash equivalents 44,967 17,625 Up 155.1

Cash and cash equivalents, beginning of period 30,387 12,762 Up 138.1

Cash and cash equivalents, end of period 75,354 30,387 Up 148.0

EBITDA AND MARGINS

	2014-12-31	2013-12-31
Net Income Margin %	-530.87	-999.06

PERFORMANCE RATIOS

	2014-12-31	2013-12-31	Change %
Return on Equity (%)	-51.47		
Return on Assets (%)	-43.57	-51.59	Reduced 15.5
Total Liabilities to Operating Cash Flow	-0.58	-0.38	Deterioration 54.1
Total Liabilities/Total Assets	0.15	0.17	Down 12.0
Current Ratio	6.53	15.53	Down 58.0

PER SHARE FIGURES

	2014-12-31	2013-12-31	Change %
Sales	85.83c	US\$4.35	Down 80.3
Cash	US\$10.05	US\$82.70	Down 87.8
Working Capital	US\$8.81	US\$78.10	Down 88.7
Shareholders' Funds	US\$8.85	-15,195.53c	Recovery
Total Liabilities	US\$1.61	US\$14.71	Down 89.1
Total Assets	US\$10.46	US\$84.27	Down 87.6
Net Tangible Assets	US\$8.85	-15,195.53c	Recovery
EPS Final	-456.0c	-4,348.0c	Reduced 89.5

BuySellSignals Financial Research provides equity research on over 48,000 companies listed in more than 90 countries and 120 markets across the world. BuySellSignals believes that every stock has a story to tell and that this story changes every day. To capture this story, BuySellSignals offers the latest pertinent and comprehensive information so that investors can make well-informed investment decisions.

BuySellSignals publishes equity research reports on each stock, sector and index daily to capture the latest market movements and sentiments. BuySellSignals eschews "hot tip" or headline investing in favour of high-quality, ultra-current, targeted technical and fundamental information including specific bullish and bearish signals for each stock. Insights that will guide you to the investments that are hard to find in today's hyperactive mainstream markets.

For further details on definitions and quotations from investing legends, [Click here](#)

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data from BuySellSignals (AFS Licence 222756) and News Bites Pty Ltd, who provide round the clock data on every Australian stock and sector. Neither BuySellSignals nor News Bites are brokers, and neither have an executing, corporate advisory or investment banking function. BuySellSignals and News Bites Pty Ltd, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. The data is sourced from annual reports and company releases and may not be fully up to date. It should be used as a guide only.
